{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:25Z","timestamp":1793640685940,"version":"4.5.1"},"reference-count":44,"publisher":null,"issue":"3","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>Relevant aspects of the pathogenesis, diagnosis, And treatment of heart failure with preserved LV EFThis review analyzes results of studies of the recent decade that focus on epidemiology, mechanisms of development, diagnostic methods, and treatments of heart failure with preserved ejection fraction (HFpEF). As expected, the prevalence of HFpEF continues to increase due to the growing contribution of comorbidities to the structure of causes for chronic heart failure (CHF), such as arterial hypertension with left ventricular hypertrophy, obesity, chronic kidney disease, as well as due to ageing of the population and decreased contributions of ischemic heart disease and myocardial infarction. Concomitant diseases are a source of low-intensity microvascular inflammation, which is currently assigned a role of a trigger mechanism eventually provoking energy deficiency, disorders of cardiomyocyte relaxation, and diffuse myocardial fibrosis. Both these processes lead to increased heart muscle rigidity and abnormally high left ventricular filling pressure (LVFP). High LVFP is associated with the development of pulmonary venous congestion and impairment of alveolar blood oxygenation, which form the clinical picture of HFpEF. Detecting high LVEF with tissue Doppler echocardiography by the E\u200a\/\u200ae\u2019 value became the instrumental basis for the HFpEF diagnostics. Recognition of inflammation and fibrosis as the key pathogenetic factors marked the main vector of modern therapy for HFpEF (anti-inflammatory and antifibrotic). The best implementation of this vector became possible with the advent of drugs from the class of angiotensin receptor and neprilysin inhibitors (ARNI), sodium-glucose cotransporter type 2 (SGLT2) inhibitors, and aldosterone antagonists. However, the efficacy of such treatments is evident only with the LV EF &lt;60-65% while at higher values, the efficacy substantially decreases. This limitation may result from the heterogenous nature of the disease and requires more advanced methods for verification of HFpEF clinical phenotypes. Among such methods, transcriptomic, metabolomic, and proteomic approaches are considered. With the use of capabilities of the \u201cmachine learning\u201d and the artificial intelligence, these approaches can become a new frontier in research to represent an important step towards personalized medicine for patients with HFpEF.<\/jats:p>","DOI":"10.18087\/cardio.2023.3.n2376","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:07:14Z","timestamp":1681992434000},"page":"3-12","source":"Crossref","is-referenced-by-count":20,"title":["Diastolic heart failure: 20 years later. \u0421urrent issues of pathoge\u00adnesis, diagnosis and treatment of heart failure with preserved LVEF"],"prefix":"10.68900","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-1393","authenticated-orcid":true,"given":"F. T.","family":"Ageev","sequence":"first","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3285-6148","authenticated-orcid":true,"given":"A. G.","family":"Ovchinnikov","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology; Evdokimov Moscow State University of Medicine and Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"ref1","unstructured":"Belenkov Yu.N., Ageev F.T., Mareev V.Yu. Meet: Diastolic heart failure. Russian Heart Failure Journal. 2000;1(2):40\u20134."},{"key":"ref2","unstructured":"Ageev F.T. Diastolic heart failure: 10 years of knowlege. Russian Heart Failure Journal. 2010;11(1):69\u201376."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Fonarow GC, Greene SJ. Classifying heart failure based on ejection fraction: imperfect but enduring. European Journal of Heart Failure. 2022;24(7):1154\u20137. DOI: 10.1002\/ejhf.2470","DOI":"10.1002\/ejhf.2470"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Haq MA ul, Wong C, Hare DL. Heart Failure With Preserved Ejection Fraction: An Insight Into Its Prevalence, Predictors, and Implications of Early Detection. Reviews in Cardiovascular Medicine. 2015;16(1):20\u20137. DOI: 10.3909\/ricm0725","DOI":"10.3909\/ricm0725"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4\u201314. DOI: 10.18087\/cardio.2021.4.n1628","DOI":"10.18087\/cardio.2021.4.n1628"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ovchinnikov AG, Arefieva TI, Potekhina AV, Filatova AYu, Ageev FT, Boytsov S\u0410. The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction. Acta Naturae. 2020;12(2):40\u201351. DOI: 10.32607\/actanaturae.10990","DOI":"10.32607\/actanaturae.10990"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal. 2019;40(26):2155\u201363. DOI: 10.1093\/eurheartj\/ehz158","DOI":"10.1093\/eurheartj\/ehz158"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Folse R, Braunwald E. Determination of Fraction of Left Ventricular Volume Ejected per Beat and of Ventricular End-Diastolic and Residual Volumes: Experimental and Clinical Observations with a Precordial Dilution Technic. Circulation. 1962;25(4):674\u201385. DOI: 10.1161\/01.CIR.25.4.674","DOI":"10.1161\/01.CIR.25.4.674"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;28(1):1-39.e14. DOI: 10.1016\/j.echo.2014.10.003","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Stewart S, Playford D, Scalia GM, Currie P, Celermajer DS, Prior D et al. Ejection fraction and mortality: a nationwide register\u2010based cohort study of 499 153 women and men. European Journal of Heart Failure. 2021;23(3):406\u201316. DOI: 10.1002\/ejhf.2047","DOI":"10.1002\/ejhf.2047"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? European Heart Journal. 2020;41(12):1249\u201357. DOI: 10.1093\/eurheartj\/ehz550","DOI":"10.1093\/eurheartj\/ehz550"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Van Essen BJ, Tromp J, ter Maaten JM, Greenberg BH, Gimpelewicz C, Felker GM et al. Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction. European Journal of Heart Failure. 2023;25(1):35\u201342. DOI: 10.1002\/ejhf.2695","DOI":"10.1002\/ejhf.2695"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rosch S, Kresoja K-P, Besler C, Fengler K, Sch\u00f6ber AR, von Roeder M et al. Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. Circulation. 2022;146(7):506\u201318. DOI: 10.1161\/CIRCULATIONAHA.122.059280","DOI":"10.1161\/CIRCULATIONAHA.122.059280"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Brener MI, Borlaug BA, Burkhoff D. HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues. Circulation. 2022;146(7):519\u201322. DOI: 10.1161\/CIRCULATIONAHA.122.060540","DOI":"10.1161\/CIRCULATIONAHA.122.060540"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609\u201320. DOI: 10.1056\/NEJMoa1908655","DOI":"10.1056\/NEJMoa1908655"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451\u201361. DOI: 10.1056\/NEJMoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Packer M, Butler J, Zannad F. Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure. 2022;24(7):1148\u201353. DOI: 10.1002\/ejhf.2457","DOI":"10.1002\/ejhf.2457"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure. 1999;1(3):211\u20137. DOI: 10.1016\/S1388-9842(99)00039-2","DOI":"10.1016\/S1388-9842(99)00039-2"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine. 2008;359(23):2456\u201367. DOI: 10.1056\/NEJMoa0805450","DOI":"10.1056\/NEJMoa0805450"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777\u201381. DOI: 10.1016\/S0140-6736(03)14285-7","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial: Ivabradine in HFpEF. European Journal of Heart Failure. 2017;19(11):1495\u2013503. DOI: 10.1002\/ejhf.876","DOI":"10.1002\/ejhf.876"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hartog JWL, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. European Journal of Heart Failure. 2011;13(8):899\u2013908. DOI: 10.1093\/eurjhf\/hfr067","DOI":"10.1093\/eurjhf\/hfr067"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370(15):1383\u201392. DOI: 10.1056\/NEJMoa1313731","DOI":"10.1056\/NEJMoa1313731"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2022;387(12):1089\u201398. DOI: 10.1056\/NEJMoa2206286","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M, Bewarder Y, Kindermann I. Ejection fraction in heart failure revisited- where does the evidence start? European Heart Journal. 2020;41(25):2363\u20135. DOI: 10.1093\/eurheartj\/ehaa281","DOI":"10.1093\/eurheartj\/ehaa281"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Jhund PS, Claggett BL, Packer M, Widimsk\u00fd J, Seferovic P et al. A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction. European Heart Journal. 2020;41(25):2356\u201362. DOI: 10.1093\/eurheartj\/ehaa184","DOI":"10.1093\/eurheartj\/ehaa184"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141(12):1001\u201326. DOI: 10.1161\/CIRCULATIONAHA.119.041886","DOI":"10.1161\/CIRCULATIONAHA.119.041886"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shah SJ. Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. Journal of Cardiovascular Translational Research. 2017;10(3):233\u201344. DOI: 10.1007\/s12265-017-9756-y","DOI":"10.1007\/s12265-017-9756-y"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zhu K, Ma T, Su Y, Pan X, Huang R, Zhang F et al. Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Frontiers in Cardiovascular Medicine. 2021;8:683418. DOI: 10.3389\/fcvm.2021.683418","DOI":"10.3389\/fcvm.2021.683418"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Uijl A, Savarese G, Vaartjes I, Dahlstr\u00f6m U, Brugts JJ, Linssen GCM et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. European Journal of Heart Failure. 2021;23(6):973\u201382. DOI: 10.1002\/ejhf.2169","DOI":"10.1002\/ejhf.2169"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ageev F.T., Ovchinnikov A.G. Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. Kardiologiia. 2022;62(7):1\u201310. DOI: 10.18087\/cardio.2022.7.n2058","DOI":"10.18087\/cardio.2022.7.n2058"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Inciardi RM, Fonarow GC, McMurray JJV, Solomon SD. Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation. 2022;145(23):1741\u20133. DOI: 10.1161\/CIRCULATIONAHA.121.058929","DOI":"10.1161\/CIRCULATIONAHA.121.058929"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. European Journal of Heart Failure. 2016;18(1):54\u201365. DOI: 10.1002\/ejhf.442","DOI":"10.1002\/ejhf.442"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Oshchepkova E.V., Lazareva N.V., Satlykova D.F., Tereshchenko S.N. The first results of the Russian register of chronic heart failure. Kardiologiia. 2015;55(5):22\u20138.","DOI":"10.18565\/cardio.2015.5.22-28"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ovchinnikov A.G., Ageev F.T., Alekhin M.N., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S. et al. The role of diastolic transthoracic stress echocardiography with incremental workload in the evaluation of heart failure with preserved ejection fraction: indications, methodology, interpretation. Kardiologiia. 2020;60(12):48\u201363. DOI: 10.18087\/cardio.2020.12.n1219","DOI":"10.18087\/cardio.2020.12.n1219"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297\u2013317. DOI: 10.1093\/eurheartj\/ehz641","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861\u201370. DOI: 10.1161\/CIRCULATIONAHA.118.034646","DOI":"10.1161\/CIRCULATIONAHA.118.034646"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Ageev F.T., Yarovaya E.B., Ovchinnikov A.G. \u0420ossibility of using European (HFA-PEFF) and American (H2FPEF) algorithms for diagnosing heart failure with preserved ejection fraction in Russian clinical practice. Kardiologiia. 2022;62(12):4\u201310. DOI: 10.18087\/cardio.2022.12.n2280","DOI":"10.18087\/cardio.2022.12.n2280"},{"key":"ref39","unstructured":"Stiles S. AHA 2008: I-PRESERVE: Strike Three for RAAS Inhibition in Preserved-LVEF Heart Failure. 2008. [Internet] Available at: https:\/\/www.medscape.com\/viewarticle\/583414"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez A, Richards AM, de Boer RA, Thum T, Arfsten H, H\u00fclsmann M et al. Cardiac remodelling \u2013 Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2022;24(6):927\u201343. DOI: 10.1002\/ejhf.2493","DOI":"10.1002\/ejhf.2493"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A et al. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020;142(21):2029\u201344. DOI: 10.1161\/CIRCULATIONAHA.120.045810","DOI":"10.1161\/CIRCULATIONAHA.120.045810"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. European Heart Journal. 2022;43(48):4991\u20135002. DOI: 10.1093\/eurheartj\/ehac495","DOI":"10.1093\/eurheartj\/ehac495"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263\u2013421. DOI: 10.1016\/j.jacc.2021.12.012","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73\u201390. DOI: 10.1161\/CIRCULATIONAHA.116.021884","DOI":"10.1161\/CIRCULATIONAHA.116.021884"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2376\/1362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:27Z","timestamp":1793639787000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2023.3.n2376","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}